AC Immune SA

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

AC Immune SA는 임상 단계 바이오 제약 회사로, 단백질 오접힘과 관련된 신경퇴행성 질환의 예방 및 치료를 위한 의약품, 치료 및 진단 제품을 발견, 설계 및 개발합니다. 동사의 SupraAntigen 및 Morphomer 플랫폼은 다양한 신경퇴행성 질환에서 흔히 발견되는 오접힘 단백질과 선택적으로 상호작용하는 생물학적 제제 및 저분자 화합물을 생성하도록 설계되었습니다. 회사는 알츠하이머병(AD) 진행을 늦추는 데 사용되는 인간화된, 형태 특이적 단일클론 항체인 Crenezumab과, 타우 단백질의 N-말단 부분을 표적으로 하며 AD 치료를 위해 타우에 결합하여 뉴런 간 확산을 늦추도록 설계된 연구 단계의 단일클론 항-타우 항체인 Semorinemab을 개발하고 있습니다. 또한 회사는 다운증후군 관련 AD 치료를 위한 ACI-24.060, 파킨슨병 치료를 위한 ACI-7104.056, 그리고 병리학적 인산화 타우에 대한 항체를 생성하도록 환자의 면역 체계를 자극하도록 설계된 ACI-35.030을 개발하고 있습니다. 이 외에도 회사는 AD 및 비-AD 타우병증을 위한 타우 진단제인 PI-2620과, 다른 신경퇴행성 질환으로부터 다계통 위축증의 감별 진단을 지원하는 알파-